Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF wild-type |
| Therapy | Lenvatinib + Pembrolizumab |
| Indication/Tumor Type | anaplastic thyroid carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF wild-type | anaplastic thyroid carcinoma | sensitive | Lenvatinib + Pembrolizumab | Phase II | Actionable | In a Phase II trial, treatment with Keytruda (pembrolizumab) and Lenvima (Lenvatinib) resulted in a median overall survival of 13 months, median progression-free survival of 5.4 months, and a best overall response rate of 36% (9/25, 1 complete, 8 partial responses) in patients with BRAF wild-type metastatic anaplastic thyroid cancer (PMID: 42673705; NCT04171622). | 42673705 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42673705) | Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. | Full reference... |